Heart-Safe anesthesia: drug may tame dangerous racing pulse
NCT ID NCT01259648
First seen Nov 17, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This study tested whether adding remifentanil, a fast-acting painkiller, to standard emergency anesthesia could prevent a dangerously fast heart rate in fragile patients. 75 adults needing rapid-sequence intubation received either a low or high dose of remifentanil or a placebo. The goal was to see if it safely controls heart rate during the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TACHYCARDIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Hospitalier Universitaire de Nîmes
Nîmes, Gard, 30029, France
-
Polyclinique Grand Sud
Nîmes, Gard, 30029, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remifentanil
What this could lead to
If it works, this could provide a safer way to manage heart rate during emergency anesthesia in fragile patients.
What could go wrong
This is a small, completed Phase 4 trial with only 75 participants, so results may not apply broadly. The drug may not significantly reduce tachycardia or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.